The University of Oxford's Oxford Vaccine Group launched Phase I clinical trials for its ChAdOx1 BDBV vaccine against the Bundibugyo virus, which is responsible for an ongoing Ebola outbreak in the northeastern Democratic Republic of the Congo, Reuters reported on July 13. Scientists will assess the vaccine's safety and the immune response in 50 healthy adults in Oxford, with vaccinations expected to start in the coming weeks following approval by British regulators.